Exchange: NASDAQ·Updated 07:56 PM EDT
News
all
press releases
TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
More News
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a...
Business Wire
TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down
TG Therapeutics misses Q2 earnings estimates, but surging Briumvi demand lifts revenues y/y and prompts higher 2026 revenue guidance. Stock falls.
Zacks
Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings
The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss
The biotech firm increased its 2026 total global revenue target to around $950 million, up from $925 million previously.
Stocktwits
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -87.81% and +4.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Earnings Preview: Amgen (AMGN) Q2 Earnings Expected to Decline
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, July 21, 2026 NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating...
PR Newswire
TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations
TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations...
Yahoo! Finance: News

Advertisement|Remove ads.